



RECEIVED

RECEIVED

AUG 21 2000

AUG 23 2000

TECH CENTER 1600/2900 ATTORNEY DOCKET NO. 04585/044001

PATENT

TECH CENTER 1600/2900

Certificate of Mailing: Date of Deposit: August 8, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Michelle P. Chicos

Michelle P. Chicos

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marchionni et al.

Art Unit: 1644

Serial No.: 09/298,121

Examiner: Nolan, P.

Filed: April 23, 1999

Title: METHOD FOR TREATING CONGESTIVE HEART FAILURE

Director of Patents  
Washington, D.C. 20231

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

In reply to the Notice To Comply (copy enclosed) mailed June 8, 2000, Applicant submits the following:

- ☒ An initial paper copy of the sequence listing and an amendment directing its entry into the specification.
- ☒ An initial copy of the sequence listing in computer readable form.
- ☒ A statement that the contents of the paper and computer readable copies are the same and contain no new matter.

RECEIVED

AUG 21 2000

TECH CENTER 1600/2900


Enclosed is a petition to extend the period for replying for one month, to and including August 8, 2000.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

August 8, 2000

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

\\Ntserver\documents\04585\04585.044001 Reply to Notice to Comply with Sequence Requirements.wpd





RECEIVED  
PATENT

ATTORNEY DOCKET NO. 04585/044001 2000

Certificate of Mailing: Date of Deposit: August 8, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Michelle P. Chicos

Printed name of person mailing correspondence

Michelle P. Chicos

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marchionni et al.

Art Unit: 1644

Serial No.: 09/298,121

Examiner: Nolan, P.

Filed: April 23, 1999

Title: METHOD FOR TREATING CONGESTIVE HEART FAILURE

Director of Patents  
Washington, D.C. 20231

STATEMENT UNDER 37 CFR §§1.821-1.825

Enclosed is an initial sequence listing in accordance with the requirements of 37 CFR §§1.821 through 1.825 and consisting of 3 pages to be inserted at the end of the above-referenced application.

As required by 37 CFR 1.821(c), the sequence listing appears as a separate part of the application. Each sequence in the application appears separately in the sequence listing and each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 CFR §1.821(d), the sequence identifiers are used throughout the

*a*

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**